Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Sadat City University

Status and phase: Withdrawn; Phase 2

Conditions: Dyslipidemias; Schizophrenia

Treatments: Drug: Placebo; Drug: Vildagliptin 50 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT04761861

10/2021NEUR

Details and patient eligibility

About

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.

Exclusion criteria

• liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups, including a placebo group

Vildagliptin

Experimental group

Description:

Vildagliptin 50 mg tablet daily

Treatment:

Drug: Vildagliptin 50 MG

Placebo

Placebo Comparator group

Description:

Placebo tablet daily

Treatment:

Drug: Placebo